Pharmaceuticals comprise a wide variety of chemical compounds designed to guarantee safe and effective therapies. Within these, the active pharmaceutical ingredients (APIs) deliver the beneficial health effects. However, they also impact the environment, especially aquatic ecosystems and water resources as a result of their use and production. The goal of TransPharm is to develop more sustainable and greener APIs that simultaneously reduce the environmental footprint and the dependence on third countries for API production.

Project goals

• Develop APIs and manufacturing methods that have less impact on the environment;
• Develop an environmental sustainability assessment system, improving life cycle assessments for pharmaceuticals;
• Identify barriers and solutions for the uptake of more environmentally sustainable pharmaceuticals within the pharmaceutical life cycle.

Consortium

The Horizon Europe Research project TransPharm is coordinated by Ghent University. Other partners are Radboud University, University of York, Kelada, Circa, Orian, Latvian Institute of organic synthesis, Leuphana University, Ecologic, Benkei and RIVM.

RIVM role

RIVM colleague Dr (Doctor) Caroline Moermond leads the work package where barriers and solutions for the uptake of more environmentally sustainable pharmaceuticals are identified. We are part of the work package that deals with designing greener APIs, and of the work package where we work on environmental sustainaility assessment of pharmaceuticals. Dr Yasmin de Wit coordinates the RIVM tasks.

Contact

For more information please send an email to info@rivm.nl

Funding

 TransPharm has received funding from the European Union’s Horizon Europe Research and Innovation Programme under Grant Agreement No 101057816.